Answers are grounded in this paper and cite their sources.
Enfortumab vedotin is an effective treatment in advanced urothelial carcinoma, even in less-selected, real-world patient populations. Our findings highlight the predictive significance of clinical and molecular factors, such as Eastern Cooperative Oncology Group performance status, Bellmunt risk scores, and prior response to chemotherapy and immunotherapy. Enfortumab vedotin (EV) is emerging as a standard of care for advanced urothelial carcinoma (UC), but identification of which patients might benefit the most or least remains an unmet need. Our aim was to identify clinical and molecular parameters associated with EV sensitivity in patients with advanced UC after failure of previous platinum and immune checkpoint inhibitor (ICI) therapy. We queried the PubMed, Embase, and Cochrane Library databases up to January 2024. The review protocol was registered on PROSPERO (CRD42023484339). The outcome measures were the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS). A total of 23 studies were included. Analyses for 1340 patients revealed a cumulative ORR of 48%, with higher rates in real-world studies (51%) than in clinical trials (44%). EV was similarly effective in bladder and upper-tract UC in terms of OS and PFS, but the ORR was slightly higher in upper-tract UC (odds ratio [OR] 1.29, 95% confidence interval [CI] 1.01–1.63; p = 0.041). The EV ORR was also significantly higher in the subgroups with a response to prior platinum (OR 2.65, 95% CI 1.04–6.72; p = 0.046) or ICI (OR 1.51, 95% CI 1.12–2.04; p = 0.017) therapy. Poor Eastern Cooperative Oncology Group (ECOG) performance status and high Bellmunt risk score were associated with poor ORR, and the presence of histology subtypes was associated with poor PFS (HR 1.62, 95% CI 1.10–2.38; p = 0.015). PD-L1 expression positivity and FGFR3 alterations were not associated with outcomes. EV is an effective therapy in advanced UC. The predictive parameters identified in our analyses, such as ECOG performance status, Bellmunt score, non-UC histology, and response to prior ICI and platinum treatment, can be used to guide optimal patient selection for EV or alternative therapies. We summarize data from published studies to identify factors that influence outcomes for patients with advanced cancer of the urinary tract treated with a drug called enfortumab vedotin. An understanding of these factors can help in personalizing therapy for patients and improving their care.
No takes yet. Share an insight, caveat, or question.
Altenni et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: